Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OMED

OncoMed Pharmaceuticals (OMED) Stock Price, News & Analysis

OncoMed Pharmaceuticals logo

About OncoMed Pharmaceuticals Stock (NASDAQ:OMED)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.89
$0.89
52-Week Range
N/A
Volume
1,201 shs
Average Volume
768,904 shs
Market Capitalization
$34.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. The company is also developing Etigilimab (Anti-TIGIT, OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia/b clinical trials for patients with advanced or metastatic solid tumors. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.

Receive OMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OMED Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Headlines

OMED Stock Analysis - Frequently Asked Questions

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) released its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.36. The biopharmaceutical company had revenue of $19.52 million for the quarter, compared to the consensus estimate of $7.97 million. OncoMed Pharmaceuticals had a negative net margin of 18.24% and a negative trailing twelve-month return on equity of 13.14%.

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoMed Pharmaceuticals investors own include Esperion Therapeutics (ESPR), NXP Semiconductors (NXPI), Bristol-Myers Squibb (BMY), Nightstar Therapeutics (NITE), GW Pharmaceuticals (GWPH), Celldex Therapeutics (CLDX) and Clovis Oncology (CLVS).

Company Calendar

Last Earnings
11/01/2018
Today
5/29/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OMED
Fax
N/A
Employees
22
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.10 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$44.42 million
Price / Cash Flow
N/A
Book Value
$1.25 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$34.43 million
Optionable
Optionable
Beta
1.86
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:OMED) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners